Marker Therapeutics, Inc.

Monthly Archives: December 2017

TPIV200

TPIV 200 is a vaccine that the immuno-oncology company TapImmune is developing as a treatment for platinum-chemotherapy resistant ovarian cancer or triple-negative breast cancer.
Read More

TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense

“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.
Read More

TapImmune Inc. Presentation Now Available for On-Demand Viewing

You can now view the presentation from last Thursday's Virtual Investor Conference call.
Read More

Immunovaccine’s Lncyte-Partnered Cancer Vaccine Shows Early Promise in Ovarian Cancer

TapImmune’s lead candidate, TPIV200, a multiple-epitope anti-folate receptor alpha (FRα) immunotherapy, with an FDA orphan drug designation, has paired up with AstraZeneca’s checkpoint inhibitor Imfinzi in platinum-resistant ovarian cancer patients.
Read More

TapImmune Appoints Richard Kenney, M.D., F.A.C.P., as Acting Chief Medical Officer

Dr. Kenney will continue to manage the Company’s ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.
Read More

TapImmune Inc. to Webcast, Live, at VirtualInvestorConferences.com December 7th

TapImmune President and CEO, Peter Hoang, to host live webcast on December 7th at 10:45am.
Read More

TapImmune Inc. (NASDAQ: TPIV) CEO Interview

Tapimmune Inc. President & CEO, Peter Hoang, participates in an interview with The Wall Street Analyzer. Take a listen.
Read More